Publications

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients Progressed to Atezolizumab plus Bevacizumab (Ab)

AuthID
P-00Z-QRG

Author(s)

Persano, M

Rimini, M

Tada, T

Suda, G

Shimose, S

Kudo, M

Yoo, C

Cheon, J

Finkelmeier, F

Lim, HY

Presa, J

Masi, G

Bergamo, F

Iavarone, MA

Cabibbo, G

Foschi, FG

Piscaglia, F

Cascinu, S

Scartozzi, M

Gardini, AC

Document Type

Abstract

Year published

2023

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 34, Pages: S1543-S1543 (1)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: DEC 01-03, 2023, Location: SINGAPORE

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2023.10.308

Wos: WOS:001122475400176

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients Progressed to Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help

Federated Authentication (Click on the image)

Lenvatinib (L) Versus Sorafenib (S) Second-Line Therapy in Hepatocellular Carcinoma (Hcc) Patients Progressed to Atezolizumab plus Bevacizumab (Ab)

Useful Links

Get Help